Antisense therapy market to witness significant growth by increasing need for antisense RNA to delay the development of disease is expected to grow at a CAGR of 19.60% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Antisense Therapy Market” that contains information from 2018 to 2032. The Antisense Therapy market is estimated to register a CAGR of 19.60% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Antisense Therapy market—GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Bio-Path Holdings Inc., Antisense Therapeutics Limited.

Market Highlights

The global antisense therapy market is accounted to register a CAGR of 19.60% during the forecast period and is estimated to reach USD 15.5 billion by 2032.

It is currently advised to use antisense oligonucleotides in cancer treatment. Despite challenges such as an unclear mechanism of action and customized administration for therapeutic uses, antisense oligonucleotides are becoming more and more popular as anticancer medications. The success of RNA-based medicinal techniques in the development of new medications has been demonstrated by the invention of the first approved mRNA vaccination. Apart from RNA vaccines, antisense oligonucleotides (ASOs) represent a novel and highly promising type of RNA-targeted therapeutics.

Segment Analysis

The global Antisense Therapy market has been segmented on Application, Route of Administration.

On the basis of Application, the market is segmented into Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardiometabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders, Others. The Genetic Disease segment was attributed to holding the largest market share in 2022. Due to growing need to treat and manage conditions such spinal muscular atrophy and Duchenne muscular dystrophy (DMD).

Based on Route of Administration, the global Antisense Therapy market has been segmented Intravenous Injections, Intrathecal Injections. The Intrathecal Injections segment was expected to hold the largest market share in 2022. Because of it is a method of administering medication that involves injecting it into the spinal canal or subarachnoid space to reach the CSF.

Regional Analysis

The global Antisense Therapy market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Antisense Therapy market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Antisense Therapy market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Antisense Therapy market comprises of Middle East, Africa, and Latin America.

The largest market share for Antisense Therapy was maintained by the North American regional sector. Antisense therapy is a promising treatment for a variety of genetic abnormalities, including uncommon illnesses. Growth in the market may be fueled by the increased need for efficient therapies as knowledge and diagnosis of certain illnesses rise. Research institutes and pharmaceutical corporations in the United States are making significant investments in the creation of antisense medicines. The market for such therapies may grow as a result of developments in technological devices, formulation, and delivery techniques.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for Antisense Therapy is driven by rising accelerated through collaboration between biotech, pharmaceutical, and academic organizations. Through partnerships, companies can gain access to resources, knowledge, and complementary technologies, which can propel market growth.

Additionally, the frequency of chronic illnesses like cancer, heart disease, and genetic abnormalities is rising significantly across the Asia Pacific area. Antisense therapy provides a fresh method of treating these illnesses, which is fueling the need for cutting-edge therapies. Healthcare spending is rising in line with the continued growth of the economies in the Asia Pacific area. The development and uptake of cutting-edge treatments like antisense technology are made possible by increased public and private sector.

Furthermore, the rest of the world's Antisense Therapy market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising use of customized administration for therapeutic. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global Antisense Therapy market is expected to reach USD 15.5 billion by 2032, at a CAGR of 19.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the increasing the development and uptake of cutting-edge treatments like antisense technology are made possible by increased public and private sector.


• Based on application, the Genetic Disease segment was attributed to holding the largest market share in 2022.


• GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Bio-Path Holdings Inc., Antisense Therapeutics Limited.